Dr. Achim Rothe


Publikationsliste – Privatdozent Dr. Achim Rothe

    1. Rothe et al, Personalized therapy in NSCLC – a single center experience, 2023, manuscript in preparation.
    2. Rothe A, Claßen A, Carney J, Hallek M, Mellinghoff SC, Scheid C, Holtick U, von Bergwelt-Baildon M, Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis., Eur J Haematol. 2020 Apr;104(4):291-298., Epub 2020 Jan 20.
    3. Rothe A, Diagnose und Therapie des Lungenkarzinoms – Umfassende und stringente Versorgung im Verbund, Deutsches Ärzteblatt 35-36/2019/ SUPPLEMENT: Perspektiven der Onkologie
    4. Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf , ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability, Oncotarget. 2015 Apr 30;6(12):10577-85.
    5. Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A., A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma, Blood, 2015 Jun 25;125(26):4024-31. Epub 2015 Apr 17.
    6. Jachimowicz,R.,Borchmann. S.Rothe, A., Multi-specific antibodies for cancer immunotherapy, BioDrugs,2014 Aug;28(4):331-43.
    7. Jancuskova T, Plachy R, Zemankova L, Hardekopf DW, Stika J, Zejskova L, Praulich I, Kreuzer KA, Rothe A, Othman MA, Kosyakova N, Pekova, S, Molecular characterization of the rare translocation t(3;10)(q26;q21) in an acute myeloid leukemia patient, Mol Cytogenet. 2014 Jul 15;7:47./1755-8166-7-47. eCollection 2014.
    8. Rothe, A.*, Jachimowicz, R.*, Borchmann*, S. (* These authors contributed equally), Madlener, M., Keßler, J., Reiners, K.S., Hansen, H.P., Ulrich, R., Chatterjee, C., Borchmann. P., Yazaki. P., Koslowsky, T.C., Engert, A., Heukamp, L., Hallek, M., Pogge von Strandmann, E., The bispecific immunoligand ULBP2-aCEA re-directs Natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer, 2013, accepted.
    9. Kahraman, D. *, Theurich, S. *, Rothe, A. * (*These authors contributed equally), Kuhnert, G., Sasse, S., Scheid, C., Dietlein. M., von Bergwelt-Baildon, M., Kobe, K., FDG-PET/CT to monitor treatment response to Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. Leuk Lymphoma, 2013, accepted.
    10. Bossaller, L and Rothe, A. Monoclonal antibody treatments for rheumatoid arthritis. Expert Opin Biol Ther. 2013, in press.
    11. Theurich, S., Wennhold, K., Holtick, U., Wedemeyer, I., Kobe, K., Kahraman, K., Shimabukuro-Vornhagen, A., Hübel, K., Rothe, A., Chemnitz, J., Hallek, M., Scheid, C., von Bergwelt-Baildon, M. CD30-targeted therapy combined with DLI in a patient with lymphoblastic T-cell PTLD: induction of clinical remission and cellular immunity. Transplantation, 2013, in press.
    12. Sasse*, S., and Rothe*, A. (* Both first authors contributed equally), Goergen, H., Eichenauer, D.A., Lohri, A., Jäger, U., Bangard, C., Böll, B., von Bergwelt Baildon, M., Theurich, S., Borchmann, P., Engert, A., Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma. Leuk Lymphoma. 2013 Mar 27.
    13. 6. Reiners, K.S., Kessler, J., Sauer, M., Rothe, A., Hansen, H., Reusch1, U., Hucke, C., Köhl, U., Dürkop, H., Engert, A., Pogge von Strandmann, E., Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013 Apr;21(4):895-903. 2013.14. Epub 2013 Mar 5.
    14. Theurich, S., Fischmann, H., Chakupurakal, G., Shimabukuro-Vornhagen, A., Chemnitz, J., Holtick, U., Rothe, A., Scheid, C., Hallek, M., Skoetz, N., von Bergwelt-Baildon, M. Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis – a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013 Apr 2. S1040-8428. 2013.03.009.
    15. Böll, B., Goergen, H., Fuchs, M., Pluetschow, A., Eich, H.T., Lohri, A., Weidmann, E., Fritsch, G., Leithäuser, M., Greil, R., Scherpe, A., Schmalz, O., Eichenauer, D.A., von Tresckow, B., Rothe, A., Diehl, V., Engert, A., Borchmann, P. ABVD in Elderly Early Stage Hodgkin Lymphoma Patients treated within the German Hodgkin Study Group (GHSG) HD10 and HD11 Trials. J Clin Oncol. 2013 Apr 20;31(12):1522-9. Epub 2013 Mar 18.
    16. Rothe, A., Sasse, S., Eichenauer, D.A., Bangard, C., Borchmann, P., and Engert, A., Brentuximab vedotin (SGN-35) for relapsed CD30-positive hematologic malignancies. Blood. 2012 Aug 16;120(7):1470-2. Epub 2012 Jul 11.
    17. Shimabukuro-Vornhagen, A., Draube, A., Liebig, T.M.,Popov, A., Rothe, A., von Bergwelt-Baildon, M.S. The properties of human CD40-activated B cells as antigen-presenting cells are not affected by PGE2, Oncol Rep. 2013 Mar;29(3):1061-5. Epub 2012 Dec 28.
    18. Shimabukuro-Vornhagen, A., Draube, A., Liebig, T.M., Rothe, A., Kochanek, M., von Bergwelt-Baildon, M.S.., The immunosuppressive factors IL-10, TGF-beta, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. J Exp Clin Cancer Res. 2012 May 16;31(1):47.
    19. Gopal, A.K., Ramchandren, R., O’Connor, O.A., Berryman, R.B., Advani, R.H. Chen, R., Smith, S.E., Cooper, M., Rothe, A., Matous, J., Grove, L.E., Zain, J., Safety and Efficacy of Brentuximab Vedotin for Hodgkin Lymphoma recurring after allogeneic transplant. Blood. 2012 Apr 17.
    20. Shimabukuro-Vornhagen A, Rothe A, Nogova L, Kochanek M, Scheid C, von Bergwelt-Baildon M. Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: a case report. J Med Case Reports. 2011 May 30;5:215.
    21. Jachimowicz RD, Fracasso G, Yazaki PJ, Power BE, Borchmann P, Engert A, Hansen HP, Reiners KS, Marie M, von Strandmann EP, Rothe A. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma. Mol Cancer Ther. 2011 Jun;10(6):1036-45. Epub 2011 Apr 27.
    22. Rothe A, Rubbert A. Recombinant proteins in rheumatology – recent advances. N Biotechnol. 2011 Sep;28(5):502-10. Epub 2011 Apr 5.
    23. Rothe, A., Power, B.E., Hudson, P.J., Therapeutic advances in rheumatology with the use of recombinant proteins. Nat Clin Pract Rheumatol. 2008 Nov;4(11):605-14. Epub 2008 Sep
    24. Rothe, A., Nathanielsz, A., Oberhäuser, F., Pogge von Strandmann, E., Engert, A., Hudson, P.J., Power, B. E., Selection of human anti-CD22 scFvs from an acute lymphocytic leukemia related scFv library with ribosome display. Biol Chem. 2008 Apr;389(4):433-9.
    25. Rothe A., Nathanielsz A., Hosse R.J., Oberhäuser F., Pogge von Strandmann E., Engert A., Hudson P.J.and Power B.E., Selection of human anti-CD28 scFvs from a T-NHL related scFv library using ribosome display. J Biotechnol. 2007 Jul 15;130(4): 448-54. Epub 2007 May 24.
    26. Pogge von Strandmann, E., Simhadri, V.R., von Tresckow, B., Sasse, S., Reiners, K.S., Hansen, H.P., Rothe, A., Böll, B., Simhadri, V.L., Borchmann, P., McKinnon, P.J., Hallek, M., and Engert., A., Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells. Immunity, 2007. 27(6): p. 965-74.
    27. Rothe, A., R.N. Surjadi, and B.E. Power, Novel proteins in emulsions using in vitro compartmentalization. Trends Biotechnol, 2006. 24(12): p. 587-92.
    28. Rothe A., Hosse R.J. and Power B.E., In vitro display technologies reveal novel BioPharmaceutics. Faseb J, 2006. 20(10):1599-610.
    29. 22. Hosse R.J., Rothe A. and Power B.E., Recombinant Proteins for Research, Diagnosis and Therapy, Diversified, Selected and Fine-tuned. Bioforum Europe, May 2006.
    30. Rothe A., Hosse R.J. and Power B.E., Ribosome display for improved biotherapeutic molecules. Expert Opin Biol Ther. 2006 Feb;6(2):177-87.
    31. Hosse R.J., Rothe A. and Power B.E., A new generation of protein display scaffolds for molecular recognition. Protein Sci. 2006 Jan;15(1):14-27.
    32. Böll B., Hansen H., Heuck F., Reiners K., Borchmann P., Rothe A., Engert A., Pogge von Strandmann E., The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood. 2005 Sep 1;106(5):1839-42. Epub 2005 May 5.
    33. Rothe A., Klimka A., Tur M.K., Pfitzner T., Huhn M. , Sasse S., Mallmann P., Engert A., Barth S., Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines. Int J Mol Med. 2004 Oct;14(4):729-35.
    34. Heuck R., Ellermann J., Borchmann P., Rothe A., Engert A., Hansen H., Pogge E., Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its anti-tumour activity against Hodgkin and anaplastic large cell lymphoma cell line. J Immunother. 2004 Sep-Oct;27(5):347-53.
    35. Rothe A., Schulz H., Elter T., Engert A., Reiser M., Rituximab monotherapy is effective in patients with poor risk refractory aggressive Non-Hodgkin-Lymphoma. Haematologica-The Hematology Journal. 2004 Jul;89(7):875-6.
    36. Rothe A., Seibold M., Hoppe T., Seifert H., Engert A., Caspar C., Karthaus M., Fatkenheuer G., Bethe U., Tintelnot K., Cornely OA., Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004 Jun;83(6):394-7. Epub 2003 Nov 27.
    37. Tur MK., Rothe A., Huhn M., Goerres U., Klimka A., Stocker M., Engert A., Fischer R., Finner R., Barth S., A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. Int J Mol Med. 2003 Apr;11(4):523-7.